Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: sam who wrote (960)	8/1/2001 4:29:45 PM
From: sam	Read Replies (1) \| Respond to of 1475

"Just looking for a silver lining in the event of rejection. Will BTRN get hit? It shouldn't...as their investment in SCS is deemed to be worthless anyway. When the stem cell plays rise, BTRN remains a flat line for the day." Well, looks like we got our answer. Evidently, as far as the stock price is concerned, BTRN's stake in SCS is LESS than worthless. No upside, but -- thanks to Forbes and CNBC -- lots of downside. Seems sellers (or shortsellers) "forgot" that fast money completely ignored BTRN on the recent runnup that brought GERN, ASTM and STEM huge percentage runs.